NCT03793166 2026-03-18
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Fudan University
University of Utah
Instituto do Cancer do Estado de São Paulo
Karolinska Institutet
General University Hospital, Prague
Haraldsplass Deaconess Hospital
Shanghai Minimally Invasive Surgery Center
Fujian Medical University